Treatment of Parkinson's disease: A survey of patients and neurologists

Clinical Drug Investigation

Volumn 27, Issue 3, 2007, Pages 207-218

  Fargel, Matthias ^a   Grobe, Bernd ^b   Oesterle, Eberhard ^c   Hastedt, Claudia ^c   Rupp, Markus ^c  

^a Psyma International Medical Marketing Research GmbH   (Germany)

^b Prophares International AG   (Switzerland)

^c Schwarz Pharma AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; ENTACAPONE; LEVODOPA; PERGOLIDE; PERGOLIDE MESILATE; PRAMIPEXOLE; ROPINIROLE; SELEGILINE; TOLCAPONE;

ADULT; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEALTH SURVEY; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PARKINSON DISEASE; PATIENT SATISFACTION; PHYSICIAN; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIPARKINSON AGENTS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION REVIEW; EUROPE; FEMALE; HEALTH CARE SURVEYS; HUMANS; INTERVIEWS; MALE; NEUROLOGY; PARKINSON DISEASE; PATIENT EDUCATION; PATIENT SATISFACTION; PATIENTS; PRACTICE GUIDELINES; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES;

EID: 33947313314     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727030-00004     Document Type: Article

References (35)

1. Schapira AHV. Science, medicine, and the future. Parkinson's disease. BMJ 1999 Jan; 318: 311-4
2. de Rijk MC, Launer LJ, Berger K, et al. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurology 2000 June; 54 (11) (Suppl 5): S21-3
3. Van den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003; 157 (11): 1015-22
4. Wooten GF, Currie LJ, Bovbjerg VE, et al. Are men at greater risk for Parkinson's disease than women? J Neurol Neurosurg Psychiatry 2004; 75: 637-9
5. Menken M, Munsat TL, Toole JF. The global burden of disease study: implications for neurology. Arch Neurol 2000; 57: 418-20
6. Huse DM, Schulman K, Orsini L, et al. Burden of illness in Parkinson's disease. Mov Disord 2005; 20 (11): 1449-54
7. Lindgren P, von Campenhausen S, Spottke E, et al. Cost of Parkinson's disease in Europe. Eur J Neurol 2005; 12 Suppl. 1: 68-73
8. Olanow CW, Jankovic J. Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Mov Disord 2005; 20 Suppl. 11: S3-10
9. Rascol O, Goetz C, Koller W, et al. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002 May; 359: 1589-98
10. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001 Jun; 56 (11 Suppl. 5): S1-88
11. Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter: initiation of treatment for Parkinson's disease. An evidence-based review. Report of the Quality Standards Subcompatient mittee of the American Academy of Neurology. Neurology 2002 Jan; 58 (1): 11-7
12. Deutsche Gesellschaft für Neurologie. Updated guideline for Parkinson syndrome (in German) [online]. Available from URL: http://www.dgn.org/221.0.html [Accessed 2005 Nov 17]
13. Italian Neurological Society/Italian Society of Clinical Neurophysiology. Guidelines for the treatment of Parkinson's disease 2002: treatment of Parkinson's disease. Neurol Sci 2003 Jun; 24 Suppl. 3: S165-213
14. Federation Française de Neurologie. Recommendations of the jury on diagnosis and treatment of Parkinson's disease (short text). Rev Neurol (Paris) 2000; 156 (Suppl. 2, Part 2): 274-80
15. Grupo de estudio de los trastomos del movimiento. Guías de práctica clínica en le enfermedad de Parkinson (in Spanish). Neurologia 1999; 14 Suppl. 5: 1-92
16. National Institute for Health and Clinical Excellence. Parkinson's disease: diagnosis and management in primary and secondary care. NICE full guideline, 2006 June [online]. Availa-controlled ble from URL: http://www.nice.org.uk/page.aspx?.o=cg035 fullguideline [Accessed 2006 July 7]
17. Bhatia K, Brooks DJ, Burn DJ, et al. Updated guidelines for the management of Parkinson's disease. Hosp Med 2001 Aug; 62(8): 456-70
18. Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs 1998; 55 Suppl. 1: 1-9
19. Goetz CG, Koller WC, Poewe W, et al. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002 Jul/Aug; 17 (Suppl. 4): S1-166
20. Kuopio A-M, Marttila RJ, Helenius H, et al. The quality of life Parkinin Parkinson's disease. Mov Disord 2000; 15 (2): 216-23
21. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000; 69: 308-12
22. The Global Parkinson's Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord 2002; 17 (1): 60-7
23. Zach M, Friedman A, Slawek J, et al. Quality of life in Polish patients with long-lasting Parkinson's disease. Mov Disord 2004; 19 (6): 667-72
24. Grosset KA, Grosset DG. Patient-perceived involvement and satisfaction in Parkinson's disease: effect on therapy decisions and quality of life. Mov Disord 2005; 20 (5): 616-9
25. Behari M, Srivastava AK, Pandey RM. Quality of life in patients with Parkinson's disease. Parkinsonism Relat Disord 2005; 11: 221-6
26. Möller JC, Körner Y, Dodel RC, et al. Pharmacotherapy of Parkinson's disease in Germany. J Neurol 2005 Aug; 252 (8): 926-35
27. The Harris Poll. The difficult lives of patients with Parkinson's disease. Health Care News (Taylor H, Leitman R, eds) 2003; 3: 15
28. Findley LJ, Baker MG. Treating neurodegenerative diseases: what patients want is not what doctors focus on. BMJ 2002 Jun; 324: 1466-7
29. Shimbo T, Goto M, Morimoto T, et al. Association between patient education and health-related quality of life in patients with Parkinson's disease. Qual Life Res 2004; 13: 81-9
30. O'Maley K, O'Sullivan J, Wollin J, et al. Teaching people with Parkinson's disease about their medication. Nursing Older People 2005 Mar; 17 (1): 14-20
31. Weiss M, Britten N. What is concordance? Pharm J 2003 Oct; 271: 493
32. Ravina BM, Fagan SC, Hart RG, et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 2003; 60: 1234-40
33. Kornick CA, Santiago-Palma J, Moryl N, et al. Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Saf 2003; 26 (13): 951-73
34. The Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003; 60: 1721-8
35. Watts RL, Jankovic J, Waters C, et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007; 68: 272-76 Clin Drug Invest 2007; 27 (3): 219-223